Lecturas Recomendadas: Terapia Hormonal de la Posmenopausia y Estrategias Preventivas


• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy post-menopausal women. JAMA 2002;288:321-333.
• Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362:419-427.
• Anderson GL, Judd HL, Kaunitz AM, et al. for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA 2003;290:1739-1748.
• Harman SM, Brinton EA, Cedars M, Lobo R, et al. The Kronos Early Estrogen Prevention Study. An ongoing trial of the effects of early initiation of HRT on coronary artery disease. Climacteric 2005;8:3-12.
• Aging, menopause, cardiovascular disease and HRT. Proceedings of the 8th IMS workshop. Climacteric 2009;12(Suppl 1).
• Center for Media and Public Affairs; commissioned by the Hormone Foundation. Analysis of media coverage of hormone therapy for menopause management: 2002 through 2007. https://www.hormone.org/Menopause/ upload/media-analysis-081309.pdf
• Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the Women’s International Study of long Duration Oestrogen after Menopause (WISDOM): a randomised.

Hormonas y Cáncer de Mama

• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
• Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032.
• Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptordefined invasive breast cancer. Int J Cancer 2008;26:1260-1268.
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138-5133.
• Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010;28:3830-3837.
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692.
• Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann NY Acad Sci 2010;1205:268-276.

Cáncer de Ovarios, Cáncer Pulmonar y otros Cánceres

• Grodstein F, Newcomb P, Stampfer M. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and metaanalysis. Am J Med 1999;106:574-582.
• Ritenbaugh C, Stanford J, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17: 2609-2618.
• Marsden J, Sturdee D. Cancer issues. Best Pract Res Clin Obstet Gynaecol 2009;23: 87-107.
• Morch L, Lokkegaard E, Andreasen A, et al. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
• Delellis Henderson K, Duan L, Sullivan-Halley J, et al. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol 2010;171:415-425.
• Chlebowski R, Anderson G, Manson J, et al. Lung cancer among postmenopausal women treated with estrogen alone in the Women’s Health Initiative randomized trial. J Natl Cancer Inst 2010;102:1413-1421.
• Freedman ND, Lacey JV Jr, Hollenbeck AR, et al. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer 2010;116:1572-1581.

Características Específicas de Género para la Enfermedad Cardiovascular en Mujeres

• Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27: 994-1005.
• Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Climacteric 2007;10:508-526.
• Executive Writing Committee, Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women – 2011 Update: A Guideline From the American Heart Association. Circulation 2011 Feb 16. Epub ahead of print.

Hormonas Posmenopáusicas y Enfermedad Coronaria

• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative.n Arch Intern Med 2006;166:357-365.
• Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-599.
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health 2006; 15:35-44.
• Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger women. Ann Intern Med 2009;122:1016-1022.
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336-340.
• Toh S, Hernández-Días S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear?: a randomized trial. Ann Intern Med 2010;152:211-217.


• Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
• Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2010 Dec 21. Epub ahead of print.
• Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric 2010;13:429-432.

Accidente Vascular Encefálico

• Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249.
• Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
• Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005;330:342.
• Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation 2006;113:2425-2434.
• Arana A, Varas C, Gonzalez-Perez A, et al. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause 2006;13:1-7.
• Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.
• Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested casecontrol study. BMJ 2010;340:c2519.
• Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011; 18:237-240.

Otros Desórdenes Neurológicos

• Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006;47: 1447-1451.
• Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008;111:127-136.
• MacGregor EA. Estrogen replacement and migraine. Maturitas 2009;63:51-55.
• Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. Mov Disord 2009;24:1359-1365.
• El-Etr M, Ghoumari A, Sitruk-Ware R, Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas 2011;68:47-51.



Por favor ingrese su comentario!